CELUW
Celularity IncNASDAQ
Key Statistics
Market Cap
—
P/E Ratio
—
EPS
$-0.87
Beta
0.70
52W High
$0.10
52W Low
$0.01
50-Day MA
$0.00
200-Day MA
$0.00
Dividend Yield
—
Profit Margin
-198.80%
Forward P/E
—
PEG Ratio
—
About Celularity Inc
Celularity Inc (CELUW) is a pioneering clinical-stage biotechnology firm dedicated to advancing innovative cell therapies derived from the human placenta. By leveraging the regenerative potential of placental cells, the company aims to tackle a range of critical health issues, including cancer, autoimmune diseases, and degenerative disorders. Its proprietary technology platform facilitates the development of off-the-shelf cellular therapies, highlighting its role in the evolving landscape of cell-based medicine. With a robust pipeline and a solid foundation of intellectual property, Celularity is strategically positioned to fulfill the growing demand for breakthrough therapeutic solutions addressing significant unmet medical needs.
Fundamentals
| Revenue (TTM) | $40.58M |
| Gross Profit (TTM) | $20.54M |
| EBITDA | $-41.35M |
| Operating Margin | -243.20% |
| Return on Equity | -6367.00% |
| Return on Assets | -25.00% |
| Revenue/Share (TTM) | $1.69 |
| Book Value | $-0.71 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | -61.30% |
| Quarterly Revenue Growth (YoY) | -43.20% |
| Shares Outstanding | 0 |
| Float | $18.42M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Data last updated: 4/10/2026